Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
botulinum toxin A + triamcinolone acetonide
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intralesional
01
Overview
A combination therapy using botulinum toxin A and triamcinolone acetonide primarily for treating hypertrophic scars and keloids. Botulinum toxin A blocks neuromuscular transmission by inhibiting acetylcholine release, while triamcinolone acetonide is a corticosteroid with anti-inflammatory properties. The combination has shown enhanced efficacy in reducing scar-related symptoms like pain and itching compared to either component alone.
- Other names
- BTA + TCATAC/BTX-ABTX-A + TCABTA + TAC
02
Targets
GR (Glucocorticoid receptor)SNAP25 (Synaptosome-associated protein 25)NGF (Nerve growth factor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on botulinum toxin A + triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on botulinum toxin A + triamcinolone acetonide.